MedTrace Logo

Safety and Efficacy of Oncoxin in Hepatocellular Carcinoma (HCC)

NCT01392131 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-12-12

No results posted yet for this study

Summary

Oncoxin is safe and results in improved survival in patients with hepatocellular carcinoma

Conditions

Interventions

DIETARY_SUPPLEMENT

Oncoxin

20 patients with hepatocellular carcinoma will receive syrup Oncoxin 25 ml bd and capsule Oncoxin 1 cap bd for 24 weeks

OTHER

Supportive treatment

patients will receive only supportive treatment. No chemotherapy, radiotherapy, tumor ablation or surgery will be performed

Sponsors & Collaborators

  • Clinical Research Organization, Dhaka, Bangladesh

    lead OTHER

Principal Investigators

  • Mamun A Mahtab, MSc MD FACG · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2012-12-31
Completion
2013-07-31

Countries

  • Bangladesh

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01392131 on ClinicalTrials.gov